Navigation Links
AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
Date:12/1/2011

IRVINE, Calif., Dec. 1, 2011 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, today announced that its agreement with OOO CardioNova ("CardioNova"), a Russian subsidiary of Maxwell Biotech Group ("Maxwell"), to license territorial development and commercialization rights for AtheroNova's AHRO-001 lead compound has been ratified by both companies.  In addition, under a separate securities purchase agreement, CardioNova will become an equity investor in AtheroNova with an initial stock purchase of up to $267,000.

Initial funding of $900,000 has been provided by Maxwell Biotech Venture Fund, Russia's premier biotech venture capital firm, to CardioNova with which to initiate Phase I human clinical studies in Russia.  The license agreement provides for AtheroNova to issue up to $3.8 million in common stock to CardioNova for funding and performing Phase I and Phase II studies of AHRO-001, to be issued in tranches based on the progress of the studies.  Successful development will enable CardioNova to realize the value of its exclusive licensing rights to develop and commercialize AHRO-001 in the territory encompassing the Russian Federation, Belarus, Ukraine, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Moldova, Azerbaijan and Armenia.

"We are pleased to have the enthusiastic support and confidence of such an internationally respected partner as Maxwell," said Thomas W. Gardner, CEO of AtheroNova.  "This commitment of resources to move into Phases I and II human clinical studies in Russia signifies a great step in the progress of AHRO-001 as a potential treatment of atherosclerosis and could help millions of patients world-wide." 

"Maxwell is delighted to be the first licensing partner for AtheroNova's AHRO-001," said Alexey Eliseev, Managing Director of Maxwell.  "We anticipate strong deman
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
2. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
3. DFB Pharmaceuticals Appoints Maxwell Lea to Vice President Business Development and Corporate Finance
4. New Promega Maxwell 16 LEV Blood DNA Kit Surpasses Concentration Standards in Less Time
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. Yongye Biotechnology International Retains CCG Investor Relations
7. ThirdBiotech Announces Kemeta as Newest Sponsor
8. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
9. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
10. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
11. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... 27, 2015 , ... Brady (NYSE:BRC), a global ... 3 Ways to GHS Labels . This video provides useful information on how ... by effectively labeling chemical containers. , “With the fourth and final deadline for ...
(Date:7/27/2015)... WORTH, Texas , July 27, 2015 ... Media Market by Type (Home-brew Media, Pre-formulated Media), by Application ... America , Europe , ... Forecast to 2019", The global biopreservation media market was valued ... to around $571.5 million by 2019, at a CAGR of ...
(Date:7/27/2015)... ... July 27, 2015 , ... Visual Assay was named as ... top 100 most innovative technologies and services of the past year. More than 70 ... Software/Services category. The winners will be announced at the 2015 R&D 100 Awards Dinner ...
(Date:7/24/2015)... San Diego, CA (PRWEB) , ... July 24, 2015 , ... ... Hospital & Referral Center in support of stem cell therapy training and clinical opportunities. ... offer this new opportunity to veterinarians in the San Diego area. Stem cell therapy ...
Breaking Biology Technology:Brady Releases “3 Roads to GHS Labels” Video 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3
... , KNOXVILLE, Tenn., Sept. 16 Marking ... colon cancer, EDP Biotech Corporation (EDP), ... today that its ColoMarker(TM) assay achieved 100 percent detection rate ... pre-clinical trials. ColoMarker is the first assay of its kind ...
... SAN DIEGO, Sept. 16 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: ... new class of small molecule compounds based on endogenous adrenal steroid ... Stock Market on September 15, 2009. , , ... Marketplace Rule 4450(a)(5) (the "Minimum Bid Price Rule") because its common ...
... Collaboration with Biomodels facilitates development of novel drug product , ... Inc., a biotechnology company developing oral antibodies for disease targets accessible ... a Phase I SBIR grant from the National Institute of Dental ... therapeutic for oral mucositis. , , Avaxia is ...
Cached Biology Technology:New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials 2New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials 3Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 2Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price 3Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 2Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis 3
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... personalized medicine for Parkinson,s disease, by investigating signs of ... cells respond to drug treatments. The study was funded ... collected skin cells from patients with genetically inherited forms ... They found that neurons derived from individuals with distinct ...
... is the way to go, if you are a primate ... orangutans, researchers have measured the energy required to navigate a ... up in the trees. Their work was presented at the ... July 2012. The findings help us to understand ...
... Laboratory of Neuro Imaging (LONI) has been responsible for ... generated by the Alzheimer,s Disease Neuroimaging Initiative (ADNI), an ... of Alzheimer,s disease. That stream of ... partners with an ambitious publicprivate effort to dig deeper ...
Cached Biology News:Patient-derived stem cells could improve drug research for Parkinson's 2Patient-derived stem cells could improve drug research for Parkinson's 3Patient-derived stem cells could improve drug research for Parkinson's 4Revolutionary project will obtain entire genome sequences in fight against Alzheimer's 2Revolutionary project will obtain entire genome sequences in fight against Alzheimer's 3
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
Request Info...
...
Biology Products: